Active Ingredient Loading in Serum: Solubility Limit, Penetration & Stability Data

Overview #

Loading a serum with actives is not just a concentration decision. It is a solubility decision, a penetration decision, and a stability decision — all at once, and all in tension with each other. When brand partners come to us with a brief that says “we want 20% vitamin C, 1% retinol, and 10% niacinamide in one serum,” the first thing we do is not start formulating. We ask: which of these do you actually need to perform, and which are label claims? Because you cannot have all three at full concentration in a single stable phase. That is the conversation we need to have before anything goes into a beaker.

How We Read a Serum Brief #

When a brief lands on our desk, the first question is not “what actives?” It is “what skin concern, what market, and what claims are you making on-pack?” Those three answers determine everything downstream — pH window, vehicle system, preservative strategy, and packaging.

A brightening serum targeting the Korean market will almost always need L-ascorbic acid at 10–20% in a low-pH aqueous base (pH 2.5–3.5). That same formula sold into the EU triggers a different conversation, because drop below pH 3.0 and you are in a grey zone for some national competent authorities interpreting EU Cosmetics Regulation 1223/2009. Most brands don’t realize this until we tell them.

A retinol serum brief is different again. The first question we ask is: “Are you claiming retinol on-pack, or are you open to retinaldehyde or a retinyl ester?” Because the answer changes the formulation complexity, the stability protocol, and the cost by a meaningful margin. Retinol at 1% in a water-based serum is genuinely difficult. We stabilize it at pH 5.0–5.5 using a citrate-phosphate buffer system, with BHT at 0.05% as an antioxidant co-stabilizer, and we still run 12-week accelerated stability at 40°C/75% RH before we sign off on a formula. Three out of five clients who request 1% retinol in an aqueous serum hit stability failure by week 8 of that protocol. The ones that pass are almost always in airless packaging.

Niacinamide is the easiest of the three to load — up to 10% is well-tolerated in most skin types and stable across a wide pH range (4.0–7.0). But combine it with high-dose vitamin C at low pH and you get niacin conversion, which causes flushing. We see this failure mode regularly when brands brief us on “vitamin C + niacinamide” combinations without specifying the pH target. Short answer: don’t try to combine these two in the same phase at low pH.

Solubility Limits and What They Actually Mean at Scale #

Solubility limits are not just textbook numbers. They are the boundary between a formula that works at 500g lab scale and one that crashes at 200kg production.

L-ascorbic acid has a water solubility of approximately 330 g/L at 20°C — so 20% is theoretically achievable in a purely aqueous system. In practice, at production scale, we see crystallization onset when the mixing temperature drops below 18°C during transfer. We lost one pilot batch because the holding tank was not temperature-controlled and the ambient temperature in the facility dropped overnight. The crystals redissolved on reheating, but the oxidation that occurred during that window failed the potency assay. We now require a minimum 22°C holding temperature for all high-dose ascorbic acid batches.

Retinol is a different problem entirely. It is oil-soluble, with essentially zero water solubility. Getting it into a water-based serum means either a solubilizer system (polysorbate 20 at 2–4× the retinol concentration is our standard starting point), an emulsion vehicle, or encapsulation. Encapsulation sounds great until you price it — roughly 3× the raw material cost for a microencapsulated retinol versus neat retinol at equivalent declared concentration. For a mass-market brief, that cost is usually a dealbreaker.

Peptides are where solubility gets quietly complicated. Most synthetic peptides are water-soluble, but some — particularly lipopeptides like palmitoyl tripeptide-1 — have limited aqueous solubility above 5 ppm. We have seen formulas that look perfectly clear at lab scale turn hazy at 50kg when the mixing shear is lower and the temperature profile is different. This is usually where projects go sideways if the brief specifies a “crystal-clear serum” with a lipopeptide complex.

For a deeper look at how we handle peptide loading specifically, see our peptide and growth factor formulation guide.

Penetration: The Gap Between Label and Skin #

This is the section most brands skip in their brief. They specify the concentration. They rarely specify the delivery target.

Penetration of actives through the stratum corneum is governed by molecular weight, lipophilicity (logP), and vehicle interaction — not just concentration. Vitamin C at 15% in a glycerin-heavy base will not penetrate as effectively as 10% in a propylene glycol/water vehicle at pH 3.0, because the lower pH increases the proportion of the uncharged, membrane-permeable form. The number on the label is not the number reaching the viable epidermis.

For retinol, the penetration story is actually well-documented. One double-blind, randomized controlled trial (n=36, 12 weeks, twice-weekly application) demonstrated a 44% increase in epidermal thickness and a statistically measurable reduction in fine line depth versus vehicle control. What that study does not tell you — and what we have learned from our own batches — is that the vehicle used in that trial was a specific emollient ester base that most brands do not specify in their brief. The penetration result is partly the retinol, partly the vehicle. We are still not fully convinced that switching to a different emollient base gives you the same clinical outcome, even at the same retinol concentration.

Hyaluronic acid is the most misunderstood penetration story in the industry. High molecular weight HA (1,500–1,800 kDa) sits on the skin surface and provides immediate hydration and a plumping effect. It does not penetrate. Low molecular weight HA (5–50 kDa) can penetrate into the upper dermis, but the evidence for meaningful biological activity at those depths is still evolving — what is acceptable to claim today may shift as regulators look more closely at this. Brands that want to claim “deep hydration” need to be specific about which fraction they are using, and at what concentration. We typically formulate with a dual-weight HA system: 0.1% high MW for surface feel, 0.05% low MW for the penetration narrative.

For our full approach to vitamin C delivery systems, see our vitamin C and antioxidant systems guide.

Premium vs. Mass-Market: Where the Specs Actually Diverge #

Honestly, most brands underestimate how different these two development tracks are — not just in ingredient cost, but in the entire formulation architecture.

The packaging line is where the cost divergence becomes real. An airless pump adds $0.40–$0.80 per unit at MOQ 1,000 units. Most indie brands cannot absorb that at launch. What we often recommend instead is a nitrogen-purged amber dropper bottle — it is not as elegant, but it extends retinol stability by approximately 30% compared to a standard clear glass dropper in our internal testing, at a fraction of the airless pump cost.

The preservative story is also worth flagging. A lot of clean beauty brands underestimate how fragile low-pH preservative systems become at production scale. Phenoxyethanol at 1.0% in a pH 3.0 vitamin C serum is technically compliant under FDA Cosmetics Guidelines, but the challenge preservation test (ISO 11930) pass rate in our lab drops significantly at that pH because the acidic environment affects the preservative’s activity spectrum. We have had batches pass at lab scale and fail the challenge test at 200kg because the pH drifted 0.2 units during scale-up. That 0.2 units matters.

Development Timeline: What to Expect #

A realistic serum development timeline from brief to production-ready formula runs 12–20 weeks depending on complexity. Here is how we actually run it.

Weeks 1–2 are brief alignment and ingredient sourcing. We will not start formulating until we have confirmed active ingredient suppliers, because the same declared ingredient from two different suppliers can behave completely differently in emulsion. We have rejected supplier switches mid-project because the new retinol source had a different particle size distribution that changed the stability profile.

Weeks 3–6 are lab-scale development. We typically run 3–5 formula iterations at 200–500g scale. This is where we resolve the solubility and compatibility issues. Most of the interesting failures happen here, which is where they should happen.

Weeks 7–10 are stability initiation and pilot scale-up to 10–20kg. This is the first real test of whether the formula survives mixing shear, temperature cycling, and packaging interaction. Gram-negative contamination at week 8 of preservation challenge is the most common failure mode we see at this stage — usually traced back to a water activity issue in the formula, not a preservative concentration issue.

Weeks 11–16 are accelerated stability readout and regulatory documentation. For EU market, this means full SCCS Scientific Opinion alignment on any novel actives, plus CPNP notification preparation. For NMPA registration via NMPA Cosmetic Regulation, add 8–12 weeks for filing if the formula contains any ingredients on the new ingredient notification list.

We haven’t fully solved the timeline compression problem for brands that want both EU and CN registration simultaneously. Our current approach works — parallel documentation tracks — but it is not elegant.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask in every kickoff. Not because we need the marketing brief — we need to know the regulatory destination and the label claim before we touch a beaker.

If you are coming to us with a serum brief, here is what we need from you upfront: target skin concern, primary active and desired on-pack concentration, target market (EU, US, CN, or multi-market), packaging preference, and retail price point. That last one is not a commercial question — it is a formulation constraint. A $15 retail serum has a COGS ceiling of roughly $3.00–$4.50 at standard margin, which means we are working with a specific ingredient budget that rules out encapsulated actives, certain peptide complexes, and premium packaging formats.

For brands targeting the premium segment, we recommend building the stability protocol into the brief from day one. Twelve weeks of accelerated stability data aligned with ICH Stability Guidelines is not optional for serious retail buyers — it is table stakes. We have seen launches delayed by 3–4 months because the brand did not budget for the full stability run upfront.

One thing we push back on regularly: brands that want to maximize the active ingredient list. A serum with eight actives is almost always harder to stabilize than one with three, and the consumer benefit is rarely additive. Pick your hero actives. Build the formula around them. We will tell you honestly if the supporting cast is helping or just adding cost and risk.

Frequently Asked Questions #

Q: We want to put “Vitamin C 15%” on the pack — is that actually stable in a water-based serum?

At 15% L-ascorbic acid in an aqueous base, you need pH 2.8–3.2 and an airtight, light-protected packaging format to get through 12 months. In our stability chamber, open-air dropper bottles at that concentration show greater than 20% potency loss by week 10 at 40°C. Airless or nitrogen-purged packaging is not optional at that concentration — it is the formula.

Q: Can we combine retinol and AHA in the same serum?

Technically yes, but we almost always push back on this brief. Retinol is most stable at pH 5.0–5.5. AHAs need pH 3.5–4.5 to be efficacious. The compromise pH of around 4.5 gives you suboptimal performance from both actives and a harder preservation challenge. Most of the time, we recommend a two-product system — or a retinol serum with a separate AHA toner — rather than trying to force both into one formula.

Q: What is the minimum order quantity for a custom serum development?

Our standard MOQ for a custom serum is 500kg finished product for mass-market specs, and 200kg for premium specs. Below those thresholds, the per-unit cost of development amortization makes the project commercially difficult. For very early-stage brands, we sometimes offer a 50kg pilot batch option, but that is a separate conversation.

Q: How long does it take to get a formula ready for EU market launch?

Realistically, 16–20 weeks from signed brief to production-ready formula with full stability data. Add 4–6 weeks for cosmetic product safety report (CPSR) and CPNP notification. If your formula contains any ingredient with a recent SCCS opinion or a concentration limit under Annex III of EU Cosmetics Regulation 1223/2009, budget for an additional 2–4 weeks of regulatory review.

Q: We’ve seen serums claiming 2% retinol — can you actually formulate that?

We can. We have. The stability data at 2% retinol in an aqueous-based serum is genuinely difficult to defend past 6 months without encapsulation or a fully anhydrous vehicle. In our internal testing, neat retinol at 2% in a standard emulsion base shows approximately 35% degradation by month 6 at 25°C/60% RH. If a brand insists on the 2% claim, we require airless packaging, a fully opaque container, and a 12-month real-time stability run before we sign off on the formula for commercial production.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.